Zdrowie i gospodarka · 24/06/2022
FDA Announces Draft Guidance on Rescinding Breakthrough Therapy Designation
The FDA is releasing a draft guidance that outlines the considerations for rescinding a breakthrough therapy designation, which is a designation granted to expedite the development and review of a breakthrough therapy.
Source: Federal Register — Food and Drug AdministrationOpen original release →